| 1. |
2022
Emily Pei-Ying Lin,Chih-Yuan Hsu,Lynne Berry,Paul Bunn,Yu Shyr.
Analysis of Cancer Survival Associated With Immune Checkpoint Inhibitors After Statistical Adjustment: A Systematic Review and Meta-analyses
. JAMA Netw Open
.2022
|
|
| 2. |
2022
Emily Pei-Ying Lin,Chih-Yuan Hsu,Jeng-Fong Chiou,Lynne Berry,Leora Horn,Paul Bunn, James Chih-Hsin Yang, Pan-Chyr Yang, Alex A Adjei, Yu Shyr.
Cox Proportional Hazard Ratios Overestimate Survival Benefit of Immune Checkpoint Inhibitors (ICI): Cox-TEL Adjustment and Meta-analyses of PD-L1 Expression and ICI Survival Benefit
. J Thorac Oncol
.2022
|
|
| 3. |
2022
Emily Pei-Ying Lin,Li-Ching Huang,Jennifer Whisenant,Sally York,Travis Osterman,Jennifer Lewis, Wade Iams, Emily Skotte, Amanda Cass, Chih-Yuan Hsu, Yu Shyr, Leora Horn.
Associations of influenza vaccination with severity of immune-related adverse events in patients with advanced thoracic cancers on immune checkpoint inhibitors
. ERJ Open Research
.2022
|
|
| 4. |
2021
Emily Pei-Ying Lin,Bo-Tsang Huang,Wei-Yun Lai,Yi-Ting Tseng,Shuenn-Chen Yang,Hao-Cheng Kuo, Pan-Chyr Yang.
PINK1-mediated inhibition of EGFR dimerization and activation impedes EGFR-driven lung tumorigenesis
. Cancer Research
.2021
;(81):1745-1757
|
|
| 5. |
2021
Hsu, Chih-Yuan,Lin, Emily Pei-Ying,Shyr, Yu.
Development and Evaluation of a Method to Correct Misinterpretation of Clinical Trial Results with Long-term Survival
. JAMA oncology
.2021
|
|
| 6. |
2020
Wang, Mai,Lin, Emily Pei-Ying,Huang, Li-Ching,Li, Chung-Yi,Shyr, Yu,Lai, Chao-Han.
Mortality of Cardiovascular Events in Patients With COPD and Preceding Hospitalization for Acute Exacerbation
. Chest
.2020
;(158):973-985
|
|
| 7. |
2020
Satya Das,Kristen K Ciombor,Sigurdis Haraldsdottir,Yoanna Pumpalova,Ibrahim H Sahin,G Pineda, Yu Shyr, Emily Pei-Ying Lin, Chih-Yuan Hsu, Shih-Kai Chu, Laura W Goff, Dana B Cardin, Mehmet A Bilen, George A Fisher, Christina Wu, Jordan Berlin.
Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy
. Oncologist
.2020
;(25):669-679
|
|
| 8. |
2019
Wei-Yun Lai,Jen-Wei Wang,Bo-Tsang Huang,Emily Pei-Ying Lin,Pan-Chyr Yang.
A novel TNF-α-targeting aptamer for TNF-α-mediated acute lung injury and acute liver failure
. Theranostics
.2019
;(9):1741-1751
|
|
| 9. |
2018
Lin Emily Pei-Ying,Hsiao Tzu-Hung,Lu Jo-yang,Wong Siao-Han,Lu Tzu-Pin,Konan Peck, Takashi Takahashi, Pan-Chyr Yang.
Translating gene signatures into a pathologic feature: Tumor necrosis predicts disease relapse in operable and stage I lung adenocarcinoma
. JCO Precision Oncology
.2018
;(2)
|
|
| 10. |
2018
Lin Emily Pei-Ying,Lin Ching-Heng,Yang Ching-Yao,Lu Tzu-Pin,Chang Shih-Ni,Tzu-Hung Hsiao, Bo-Tsang Huang, Chong-Jen Yu, K. Arnold Chan, Pan-Chyr Yang.
Population-based cohort study reveals distinct associations between female lung cancer and breast cancer in Taiwan
. JCO clinical cancer informatics
.2018
|
|
| 11. |
2017
Huang Bo-Tsang,Lai Wei-Yun,Chang Yi-Chung,Wang Jen-Wei,Yeh Shauh-Der,Emily Pei-Ying Lin, Pan-Chyr Yang.
A CTLA-4 Antagonizing DNA Aptamer with Antitumor Effect
. Molecular Therapy - Nucleic Acids
.2017
;(8):520-528
|
|
| 12. |
2017
Pei-Ying Lin,Hsuan-Yu Chen ,Sung-Liang Yu ,Pan-Chyr Yang .
Turning diversity toward precision
. Journal of the National Cancer Institute
.2017
;(109)
|
|